Hess, J L
Akutagava-Martins, G C
Patak, J D
Glatt, S J
Faraone, S V
Article History
Received: 31 March 2017
Revised: 17 August 2017
Accepted: 24 August 2017
First Online: 28 November 2017
Conflict of Interest
: In the past year, Dr Faraone received income, potential income, travel expenses continuing education support and/or research support from Lundbeck, Rhodes, Arbor, KenPharm, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA, Sunovion, Genomind and Neurolifesciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received support from: Shire, Neurovance, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr Faraone receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is principal investigator of ExternalRef removed. All other authors declare no conflict of interest.